http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 17:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26600030.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees. </p><p> The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26600030.html Wed, 03 Jun 2026 17:00:00 -0400 O.13305050 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26600030.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees. </p><p> The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26600030.html Wed, 03 Jun 2026 17:00:00 -0400 O.13305050 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26600030.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees. </p><p> The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26600030.html Wed, 03 Jun 2026 17:00:00 -0400 O.13305050 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26600030.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees. </p><p> The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26600030.html Wed, 03 Jun 2026 17:00:00 -0400 O.13305050 PBYI http://www.streetinsider.com/Earnings/Puma+Biotech+%28PBYI%29+Misses+Q1+EPS+by+4c%2C+provides+guidance/26454683.html <p>Puma Biotech (NASDAQ: PBYI) reported Q1 EPS of ($0.04), $0.04 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $44.8 million versus the consensus estimate of $49 million.</p><p><strong>GUIDANCE:</strong></p><p>Puma Biotech sees Q2 2026 revenue of $52-55 million, versus the consensus of $52 million.</p><p>For earnings history and earnings-related data on Puma Biotech (PBYI) <a href="http://www.streetinsider.com/ec_earnings.php?q=PBYI">click here</a>.</p> http://www.streetinsider.com/Earnings/Puma+Biotech+%28PBYI%29+Misses+Q1+EPS+by+4c%2C+provides+guidance/26454683.html Thu, 07 May 2026 16:46:53 -0400 PBYI http://www.streetinsider.com/Guidance/Puma+Biotech+%28PBYI%29+Misses+Q1+EPS+by+4c%2C+provides+guidance/26454683.html <p>Puma Biotech (NASDAQ: PBYI) reported Q1 EPS of ($0.04), $0.04 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $44.8 million versus the consensus estimate of $49 million.</p><p><strong>GUIDANCE:</strong></p><p>Puma Biotech sees Q2 2026 revenue of $52-55 million, versus the consensus of $52 million.</p><p>For earnings history and earnings-related data on Puma Biotech (PBYI) <a href="http://www.streetinsider.com/ec_earnings.php?q=PBYI">click here</a>.</p> http://www.streetinsider.com/Guidance/Puma+Biotech+%28PBYI%29+Misses+Q1+EPS+by+4c%2C+provides+guidance/26454683.html Thu, 07 May 2026 16:46:53 -0400 PBYI http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Mar+31/26454551.html si-local-file:///var/storage/secattach/20260507/26454551.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Mar+31/26454551.html Thu, 07 May 2026 16:41:00 -0400 O.13305050 PBYI http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Mar+31/26454551.html si-local-file:///var/storage/secattach/20260507/26454551.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Mar+31/26454551.html Thu, 07 May 2026 16:41:00 -0400 O.13305050 PBYI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+May+07/26454350.html si-local-file:///var/storage/secattach/20260507/26454350.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+May+07/26454350.html Thu, 07 May 2026 16:33:00 -0400 O.13305050 PBYI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+May+07/26454350.html si-local-file:///var/storage/secattach/20260507/26454350.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+May+07/26454350.html Thu, 07 May 2026 16:33:00 -0400 O.13305050 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html <p class="bwalignc"> <b><i>Raising 2026 Revenue and Net Income Guidance Based on </i><i>Increased Demand for NERLYNX</i></b> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025. </p><p> Based on accounting principles generally accepted http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+First+Quarter+2026+Financial+Results/26452891.html Thu, 07 May 2026 16:05:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26445454.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 59,750 shares of Puma common stock to six new non-executive employees. </p><p> The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26445454.html Wed, 06 May 2026 17:15:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26445454.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 59,750 shares of Puma common stock to six new non-executive employees. </p><p> The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26445454.html Wed, 06 May 2026 17:15:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26445454.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 59,750 shares of Puma common stock to six new non-executive employees. </p><p> The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Inducement+Awards+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26445454.html Wed, 06 May 2026 17:15:00 -0400 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI